

Neuroalivio®

Behavioral disorder modifier for dogs in palatable tablets.

Formula

Each palatable tablet contains:

Buspirone40.0 mg
Excipients q.s. 2000.0 mg

Indications

Neuroalivio is a behavior modifier for animals' abnormal conduct caused by mild or severe anxiety such as:

- * Separation anxiety disorder evidenced by damages such as: damages caused during the owners' absence, excessive barking and wailing, bowel movement and urine incontinence in inappropriate places, except for the normal marking of males.
- * Compulsive behavior evidenced by: tail chasing, acral lick granuloma, flank licking.
- * Dominance aggression or fearful aggression evidenced by: threatening growling when receiving orders, lack of obedience.
- * Adaptation issues towards new situations such as: the presence of a new member in the house (baby, new animals); temporary or definitive absence of a family member; adjustment to changes of environment.
- * Slightly fearful behavior evidenced by: refusal to leave the house; difficulties in walking during strolls.

Neuroalivio also eases the correctional learning of behavioral disorders.

Important notice: In order to achieve maximum therapeutic effect of Neuroalivio, the treatment should be given with the corrective therapy for the underlying pathology.

Dosage and Administration

Dogs: 2 to 4 mg/kg daily, divided in two doses with a 12-hour interval. The daily dose is equivalent to half (1/2) a tablet given every 12 hours for an animal of 10 to 20 kg of bodyweight. Buspirone needs approximately 15 days to act as a modulator of serotonin in the animal's brain. Therefore, the expected clinical response increases gradually and is evident to the owner 15 to 30 days from the beginning of the treatment.

The indicated dose is for orientation purposes only and produces a response in most of the cases. The length of the treatment will depend upon the clinical cause and the patient's response to medication.

Package

Container with 30 grooved palatable tablets.